Christophe Yannick Calvet
Bristol-Myers Squibb (United States) · 46 works · 3,442 citations · h-index 10
Top works
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells
- 1276P Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
- Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
- The promising alliance of anti-cancer electrochemotherapy with immunotherapy
- The Culture of Cancer Cell Lines as Tumorspheres Does Not Systematically Result in Cancer Stem Cell Enrichment
- Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
- Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
- Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo
- Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
- Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice
- OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
- Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
- MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer
- Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
- P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting
- Abstract PR003: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
- Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
- IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany